Skip to content

A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients

Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01311609
Enrollment
300
Registered
2011-03-09
Start date
2010-11-30
Completion date
2011-07-31
Last updated
2012-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Dry Eye

Keywords

Systane, Dry Eye

Brief summary

This study is a multi-site, unmasked PMS Study. The purpose of the study is to evaluate the physical effects of Systane Lubricant Eye Drops.

Detailed description

This study is a multi-site, unmasked PMS Study. The purpose of the study is to evaluate the physical effects of Systane Lubricant Eye Drops. The assessed effects include: corneal and conjunctival staining, and ocular signs and symptoms. This is a two week prospective study.

Interventions

OTHERSystane

Systane Lubricant Eye Drops \[1-2 Drops in each eye four times daily (QID)\]

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older, of both sexes, and any race. * Willing and able to make all required visits and follow study instructions. * A sodium fluorescein corneal staining sum of \>/ 3 in either eye. A best-corrected visual acuity of 0.6 log MAR or better in each eye as assessed during an ETDRS chart

Exclusion criteria

* A history or evidence of ocular or intraocular surgery in either eye within the past 6 months. * Lasik patients can be included if Lasik surgery was \> 6 months prior to the initiation of the study. * A history of intolerance or hypersensitivity to any component of the study medications.

Design outcomes

Primary

MeasureTime frame
Corneal StainingVisit 2 (Week 2) - change from baseline
Best-corrected visual acuityVisit 2 (Week 2) - change from baseline

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026